Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Asthma
Phase Not Applicable
Enrollment 160
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study incorporates objectives directed at two subject cohorts: 1. Uncontrolled Adult and Pediatric Asthma Subjects: To demonstrate a statistically significant and clinically meaningful decline in Point Of Care (POC) FeNO as measured by the fenoTRACK device, after an approximately 2-week course of corticosteroid therapy in adults and children with non-steroid treated uncontrolled asthma. 2. Controlled Adult and Pediatric Asthma Subjects: * To evaluate within-session clinical precision during Visit 1 and Visit 2 for the fenoTRACK device for simulated at home FeNO, and at POC * To evaluate within-session clinical precision for home fenoTRACK use

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: fenoTRACK Device — Home FeNO Monitoring: FeNO measurement will be performed. POC Longitudinal Response to Treatment: FeNO measurement will be performed in the office both the simulated home environment and POC environment.

Primary Outcomes

  • Uncontrolled Cohort - Magnitude of change in FeNO Values (Visit 2 (Day 14))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-17
Completion: 2026-09-30
Eligibility
Age: 5 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Biometry Inc
Principal Investigators:
  • Philip E. Silkoff, MD (PRINCIPAL_INVESTIGATOR) - Precision ClinOps LLC
Contact Information
Study Contact:
Vani Bhagwat, M.Sc.
647-331-4256
vbhagwat@precisionclinops.com
Ming Lee, B.Sc.
647-533-8001
mlee@precisionclinops.com
Tara Clary
209-951-6741
tarclry@aol.com
Bensch Clinical Research LLC
Interventions
  • Device: fenoTRACK Device — Home FeNO Monitoring: FeNO measurement will be performed. POC Longitudinal Response to Treatment: FeNO measurement will be performed in the office both the simulated home environment and POC environment.
Study Locations (13 sites)
Bensch Clinical Research LLC, Stockton, California 95207 United States
AllerVie Clinical Research, Panama City, Florida 32405 United States
AllerVie Clinical Research, Columbus, Georgia 31904 United States
Paul A Shapero MD, Bangor, Maine 04401 United States
AllerVie Clinical Research, Ellicott City, Maryland 21043 United States
AllerVie Clinical Research, Glenn Dale, Maryland 20769 United States
Nebraska Medical Research Institute, Inc., Bellevue, Nebraska 68123-4303 United States
Allergy Partners Clinical Research, Asheville, North Carolina 28803 United States
Toledo Institute of Clinical Research Inc, Toledo, Ohio 43617 United States
Orion Clinical Research, Austin, Texas 78759 United States
Eligibility Criteria
Inclusion Criteria Uncontrolled Cohort: 1. The subject is male or female age 5 years and above 2. The subject and/or their Legally Authorized Representative (LAR) in the case of a minor has signed an Informed Consent Form (ICF) and Assent (as applicable per IRB requirements) and understands the risks and benefits of the study 3. The subject has a diagnosis of asthma 4. The subject is willing and able to perform all study procedures 5. The subject must have uncontrolled asthma as defined by the presence on at least 2 days per week (can be non-consecutive days) in the 7 days prior to V1 of at least 3 symptoms from the following list: i. Cough ii. Wheezing iii. Shortness of breath iv. Chest tightness v. Nocturnal awakening with asthma vi. Limitation in activity due to asthma 6. The subject has a FeNO value based on the first measurement of at least 30 ppb if an adult or at least 25 ppb if \<18 years old measured on a cleared FeNO device (e.g., NIOX VERO®) Inclusion Criteria Controlled Cohort: 1. The subject is male or female age 5 years and above 2. The subject and/or their Legally Authorized Representative (LAR) in the case of a minor has signed an Informed Consent Form (ICF) and Assent (as applicable per IRB requirements) and understands the risks and benefits of the study 3. The subject has an established diagnosis of asthma for at least 180 days prior to V1 4. The subject is willing and able to perform all study procedures Exclusion Criteria Uncontrolled: 1. The subject is in need of immediate referral to the emergency department 2. The subject has taken the following medications in the indicated period before V1: 1. OCS within 4 weeks 2. ICS within 2 weeks 3. Biologic therapies (e.g., omalizumab or dupilumab) within 12 weeks. Note: Use of as needed ICS+SABA is also exclusionary in the 2 weeks prior to V1 3. The subject has a contraindication to corticosteroids. 4. The subject has demonstrated significant non-compliance during a previous clinical trial 5. The subject participated in any clinical study involving a drug, biologic, or device within 30 days prior to V1 or within 5 half-lives for drugs, whichever duration is shorter 6. The subject has other significant respiratory conditions, e.g., Chronic Obstructive Pulmonary Disease, cystic fibrosis 7. Subject is an employee/relative of the following: 1. Biometry Inc. 2. Contract Research Organization(s) running the study 3. Investigational Site 4. Study Vendors 8. Any other condition(s), that in the Investigator's opinion, make it undesirable for the subject to participate in the study 9. A ≥ 10 pack-year history of smoking or smoking in the 180 days prior to V1 (pack years = average packs/day x years of exposure) Note: smoking includes cigarettes, electronic cigarettes, cigars, and chewing or dipping tobacco 10. Pregnant or nursing subjects Exclusion Criteria Controlled: 1. The subject has other significant respiratory conditions, e.g., Chronic Obstructive Pulmonary Disease, cystic fibrosis 2. The subject has demonstrated significant non-compliance during a previous clinical trial 3. The subject participated in any clinical study involving a drug, biologic, or device within 30 days prior to V1 or within 5 half-lives for drugs, whichever duration is shorter. 4. Subject is an employee/relative of the following: 1. Biometry Inc. 2. Contract Research Organization(s) running the study 3. Investigational Site 4. Study Vendors 5. Any other condition(s), that in the Investigator's opinion, make it undesirable for the subject to participate in the study 6. A ≥ 10 pack-year history of smoking or smoking in the 180 days prior to V1 (pack years = average packs/day x years of exposure) Note: smoking includes cigarettes, electronic cigarettes, cigars, and chewing or dipping tobacco 7. Pregnant or nursing subjects
Conditions Asthma
Phase NA
Enrollment 22
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is characterized by airway inflammation and hyperinflation that flattens the diaphragm and increases reliance on accessory neck muscles. Chronic overuse shortens these muscles and promotes forward head posture (FHP), which in turn compromises rib-cage motion and respiratory mechanics. Correcting FHP alongside breathing retraining may therefore improve lung function and symptoms in asthma. This interventional, parallel-group study investigates the combined effects of McKenzie neck exercises with two different breathing approaches on lung function, chest expansion, posture, and quality of life in adults with asthma. Participants are allocated to two groups for a 4-week program: Group A performs McKenzie neck exercises plus Pilates-based breathing; Group B performs McKenzie neck exercises plus Buteyko breathing.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Pilates Breathing Combined with McKenzie Neck Exercises — Participants in this group will undergo a four-week intervention program combining McKenzie neck exercises with Pilates-based breathing techniques. The McKenzie exercises will be performed at an intensity of five repetitions per exercise during the first two weeks, progressing to ten repetitions per exercise in the third and fourth weeks. Pilates breathing will begin with two sets of ten repetitions in the first and second weeks, progress to three sets of ten repetitions in the third week, and further increase to four sets of ten repetitions in the fourth week. The intervention will be carried out three days per week on alternate days.
  • Procedure: McKenzie Neck Exercises with Buteyko Breathing — Participants in this group will undergo a four-week intervention program combining McKenzie neck exercises with Pilates-based breathing techniques. The McKenzie exercises will be performed at an intensity of five repetitions per exercise during the first two weeks, progressing to ten repetitions per exercise in the third and fourth weeks. Pilates breathing will begin with two sets of ten repetitions in the first and second weeks, progress to three sets of ten repetitions in the third week, and further increase to four sets of ten repetitions in the fourth week. The intervention will be carried out three days per week on alternate days

Primary Outcomes

  • Chest Expansion (4 weeks)
  • Lung Functions (04 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-20
Completion: 2026-02-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 22 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Foundation University Islamabad
Contact Information
Study Contact:
Arzoo Bashir Awan, DPT
03215770272
arzoobashir66@gmail.com
Sana Bashir, MS-CPPT
03218529475
drsana.bashir@fui.edu.pk
FURQAN Ahmed Siddiqi, PhD in Rehabilitation Sciences
923004414981
principal.fucp@fui.edu.pk
Foundation University College of Physical Therapy, Islamabad, 44000
Interventions
  • Procedure: Pilates Breathing Combined with McKenzie Neck Exercises — Participants in this group will undergo a four-week intervention program combining McKenzie neck exercises with Pilates-based breathing techniques. The McKenzie exercises will be performed at an intensity of five repetitions per exercise during the first two weeks, progressing to ten repetitions per exercise in the third and fourth weeks. Pilates breathing will begin with two sets of ten repetitions in the first and second weeks, progress to three sets of ten repetitions in the third week, and further increase to four sets of ten repetitions in the fourth week. The intervention will be carried out three days per week on alternate days.
  • Procedure: McKenzie Neck Exercises with Buteyko Breathing — Participants in this group will undergo a four-week intervention program combining McKenzie neck exercises with Pilates-based breathing techniques. The McKenzie exercises will be performed at an intensity of five repetitions per exercise during the first two weeks, progressing to ten repetitions per exercise in the third and fourth weeks. Pilates breathing will begin with two sets of ten repetitions in the first and second weeks, progress to three sets of ten repetitions in the third week, and further increase to four sets of ten repetitions in the fourth week. The intervention will be carried out three days per week on alternate days
Study Locations (1 sites)
Foundation University College of Physical Therapy, Islamabad, 44000, Islamabad, 44000 Pakistan
Eligibility Criteria
Inclusion Criteria: * Age group 18-40years * Both males and females * Individuals clinically diagnosed with asthma that is well controlled (Level 1 and Level 2) with FHP * Not participated in any structured exercise regime for improving lung function during the past 6 months. * Individuals well tolerated with a current exercise plan of combination exercises. (Buteyko breathing/Pilate breathing and McKenzie neck exercises Exclusion Criteria: * -Level 3 and 4 asthma or status asthmatics. * Any congenital deformity of the chest wall * Any active infections like fever, TB * Those with any contraindication to exercise testing or training. * Recent history of any chest wall trauma * Any abdominal or cardio thoracic surgery * Any psychiatric illness * Unstable Cardiopulmonary disease i.e. unstable angina, heart failure, recent MI. * Unstable hemodynamic parameters (arterial pressure \>140mmhg systolic and \>90mmhg for diastolic * Pregnancy * Previous or parallel participation in interventional programs.
Conditions Coronary Artery Disease, Diabete Mellitu...
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this observational study is to understand the impact of polypharmacy on the prognosis of elderly patients with chronic diseases. The main research question it aims to address is: Does polypharmacy affect the prognosis of elderly patients with chronic diseases? Elderly patients with chronic diseases will be asked to complete online survey questions regarding their disease prognosis over a 2-year period.

Design

Study type: Observational Observational model: Ecologic Or Community Time perspective: Cross Sectional

Primary Outcomes

  • Assessing the current status of polypharmacy in elderly patients with chronic diseases in Shaanxi Province via cluster sampling questionnaire survey (Start from enrollment to the end of the study at 2 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-01
Completion: 2027-09-30
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xijing Hospital
Contact Information
Study Contact:
Ming Yuan, MD, PhD
029-84775188
1446534236@qq.com
Interventions
N/A
Study Locations (1 sites)
Xijing Hospital, Xi'an, Shaanxi 710032 China
Eligibility Criteria
Inclusion Criteria: * Patients aged 65 years or older with at least one chronic disease Exclusion Criteria: * Patients without chronic diseases * Patients refused to participate in the study * Patients with unstable vital signs
Conditions Breast Cancer
Phase PHASE2
Enrollment 100
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Carboplatin — All of the treatment being received by the study participants during the course of the study is standard of care.
  • Drug: Docetaxel — All of the treatment being received by the study participants during the course of the study is standard of care.
  • Drug: Trastuzumab (or biosimilar) — All of the treatment being received by the study participants during the course of the study is standard of care.
  • Drug: Pertuzumab (or biosimilar) — All of the treatment being received by the study participants during the course of the study is standard of care.

Primary Outcomes

  • Pathologic complete response (pCR) rate in the breast and axilla in the two treatment arms (At time of breast surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-11-14
Completion: 2031-05-14
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Kansas Medical Center
Principal Investigators:
  • Yiduo Hu, MD (PRINCIPAL_INVESTIGATOR) - University of Kansas Medical Center
Contact Information
Study Contact:
KUCC Navigation
913-588-3671
kucc_navigation@kumc.edu
Clinical Trials Nurse Navigator
913-945-7552
ctnursenav@kumc.edu
The University of Kansas Cancer Center (KUCC)
Clinical Trial Nurse Navigator
913-945-7552
ctnursenav@kumc.edu
The University of Kansas Cancer Center - Westwood
Interventions
  • Drug: Carboplatin — All of the treatment being received by the study participants during the course of the study is standard of care.
  • Drug: Docetaxel — All of the treatment being received by the study participants during the course of the study is standard of care.
  • Drug: Trastuzumab (or biosimilar) — All of the treatment being received by the study participants during the course of the study is standard of care.
  • Drug: Pertuzumab (or biosimilar) — All of the treatment being received by the study participants during the course of the study is standard of care.
Study Locations (8 sites)
The University of Kansas Cancer Center (KUCC), Fairway, Kansas 66205 United States
The University of Kansas Cancer Center - Westwood, Kansas City, Kansas 66205 United States
KUCC - Indian Creek, Overland Park, Kansas 66211 United States
KUCC - Overland Park, Overland Park, Kansas 66215 United States
KUCC - Briarcliff, Westwood, Kansas 66205 United States
KUCC - Olathe, Westwood, Kansas 66205 United States
The University of Kansas Cancer Center - North, Kansas City, Missouri 64154 United States
KUCC - Lee's Summit, Lee's Summit, Missouri 64064 United States
Eligibility Criteria
Inclusion Criteria: * Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent * 18 years of age or older * Histologically confirmed cT2-T3 N0-N2, cT1 N1-N2, or cTX N1-N2 HER2 positive breast cancer (The invasive tumor must be HER2-positive based on the current ASCO-CAP guidelines; Patients are eligible regardless of estrogen receptor (ER) or progesterone receptor (PR) expression status. However, percentage of both ER and PR positivity must be documented in the pathology report.) * No previous ipsilateral breast surgery for the current breast cancer * No previous chemotherapy, anti-HER2 therapy, immunotherapy, endocrine therapy, or radiotherapy for the current breast cancer * ECOG Performance Status 0-1 documented within 28 days prior to the start of study treatment (Appendix A) * Breast and axillary imaging (including mammogram, ultrasound and/or MRI, per standard of care) within 49 days (7 weeks) prior to treatment initiation * Subjects with clinically and/or radiographically abnormal axillary or internal mammary lymph nodes should have pathologic confirmation of disease status with image-guided biopsy or fine needle aspiration unless deemed medically unsafe * Co-enrollment in the PRO-HER2 (HSC #160944) observational registry protocol * Archival breast tumor tissue has been obtained or has been requested for use, which should include either a formalin-fixed paraffin-embedded (FFPE) block, or sixteen slides (fourteen 5-micron uncharged unstained slides plus either two H\&E slides or two 5-micron charged unstained slides) - from primary breast tumor only. * Subjects with bilateral synchronous HER2 positive breast cancer are eligible if they meet other eligibility criteria * Neuropathy: No baseline grade 2 or above neuropathy * Not pregnant, not breastfeeding, and at least one of the following applies: Not a woman of reproductive potential as defined by institutional standards; A woman of reproductive potential who agrees to follow contraceptive guidelines per institutional standards * Adequate organ function, defined as follows: Hematologic (assessed ≤ 21 days of treatment initiation): Absolute neutrophil count ≥ 1,500/μL (with the exception of patients with documented Fy(a-/b-) (Duffy null) immunophenotype, in which case absolute neutrophil count ≥1,200/uL is allowed), Platelets ≥ 100,000/μL, Leukocytes ≥ 3,000/μL, Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L (must be met without erythropoietin dependency and without erythrocyte transfusion within the last two weeks); Hepatic (assessed ≤ 21 days of treatment initiation): Total bilirubin ≤ 1.5x ULN, AST(SGOT) and ALT(SPGT) ≤ 2x ULN, Serum albumin ≥ 3.0 g/dL; Cardiac (assessed ≤ 49 days of treatment initiation): Normal baseline echocardiogram or MUGA scan including LVEF ≥ 50%, per standard of care Exclusion Criteria: * Current or anticipated use of other investigational agents while participating in this study * Clinically or radiographically detected metastatic disease * Inflammatory breast cancer * Prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the treatment regimen. Note: Patients with squamous cell or basal cell carcinoma of the skin, ductal carcinoma in situ (DCIS) of the breast, or carcinoma in situ (CIS) of the uterine cervix who have undergone definitive therapy are not excluded from participation * History of allergic reactions attributed to carboplatin, docetaxel, trastuzumab, or pertuzumab * History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of this study, interfere with the subject's participation for the full duration of the study, or it is not in the best interest of the subject to participate, in the opinion of the treating investigator * Pregnancy, breastfeeding, or expecting to conceive within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment. There is a potential for congenital abnormalities and for this regimen to harm breastfeeding infants.
Conditions Depressive Disorder, Temporal Interferen...
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To investigate the effect of Temporal Interference Stimulation (TIS) on associative memory (AM) in patients with depressive disorder

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Device: Temporal Interference Stimulation (TIS) — The total stimulation duration was 30 minutes, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end.
  • Device: Sham temporal interference stimulation (TIS) — Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation

Primary Outcomes

  • face-word assciative memory task score (baseline and immediately after the intervention)
  • Change in Hamilton Depression Rating Scale (HAMD) Score (baseline and immediately after the intervention)
  • Change in the Patient Health Questionnaire-15 (PHQ-15) scale (baseline and immediately after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2026-06
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Second Hospital of Anhui Medical University
Contact Information
Study Contact:
Yanghua Tian, PhD
0551 6599 7278
zylykd@163.com
Yanghua Tian, PhD
0551 6599 7278
ayfytyh@126.com
Anhui Medical University
Yanghua Tian, PhD
0551 6599 7278
ayfytyh@126.com
Anhui Mental Health Center
Interventions
  • Device: Temporal Interference Stimulation (TIS) — The total stimulation duration was 30 minutes, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end.
  • Device: Sham temporal interference stimulation (TIS) — Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation
Study Locations (2 sites)
Anhui Medical University, Hefei, Anhui China
Anhui Mental Health Center, Hefei, Anhui China
Eligibility Criteria
Inclusion Criteria: * the patients were diagnosed by more than 2 psychiatrists and met the diagnostic criteria of DSM-5 for depression, and HAMD\>17, BSS\>6, PHQ-15\>5. * the age ranged from 18 to 65 years old, and the length of education was more than 5 years. * the visual acuity or corrected visual acuity is normal, right-handed, can cooperate with the completion of various experimental tests. Exclusion Criteria: * accompanied by severe somatic diseases, such as severe heart, liver, renal insufficiency and so on. * accompanied by other neurological diseases, such as stroke, epilepsy and so on. pregnant and lactating women. * accompanied by other mental disorders, such as drug abuse, schizophrenia, schizophrenic affective
Conditions Glaucoma
Phase NA
Enrollment 1040
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma is major cause of irreversible blindness and is characterized by optic nerve damage and visual field loss. Screening for glaucoma is challenging due to lack of a simple, accurate, cost-efficient and standardized process. Artificial intelligence, (AI) especially deep learning (DL) algorithms have potential to automate glaucoma detection, but have to be evaluated in real world settings, before public deployment. This study aims to evaluate the screening accuracy of a DL algorithm for glaucoma detection using colour fundus photographs (CFP) in a pragmatic randomised control trial (RCT). The algorithm will be tested in 1040 eligible patients with diabetes, recruited from the Diabetes \& Metabolism Centre's clinics under the Singapore Integrated Diabetic Retinopathy Program (SiDRP) and randomized to 2 arms: AI-assisted model vs current standard of care (grader assessment). The performance of both arms will be compared to performance of study ophthalmologist in diagnosing glaucoma. We hypothesize that the DL model has better screening performance in detecting glaucoma in the community, compared to the current practice method.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Single

Interventions / Regimen

  • Diagnostic Test: Artificial Intelligence model to detect glaucoma — A Vision Transformer model to detect glaucoma from fundus photos
  • Other: No intervention — Control group with current practice model by human graders

Primary Outcomes

  • Evaluation of model performance (At study completion (after all fundus images have been graded and data collection is finalized; approximately within 12 months of study initiation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-17
Completion: 2027-03
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1040 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Singapore Eye Research Institute
Collaborators: Singapore General Hospital, SingHealth Polyclinics
Principal Investigators:
  • Ching-Yu Cheng, MD, PhD (PRINCIPAL_INVESTIGATOR) - Singapore Eye Research Institute
Contact Information
Study Contact:
Ching-Yu Cheng, MD, PhD
65767277
chingyu.cheng@duke-nus.edu.sg
Lavanya Raghavan, MD
65767201
raghavan.lavanya@seri.com.sg
Ching-Yu Cheng, MD, PhD
65767277
Singapore National Eye Centre
Interventions
  • Diagnostic Test: Artificial Intelligence model to detect glaucoma — A Vision Transformer model to detect glaucoma from fundus photos
  • Other: No intervention — Control group with current practice model by human graders
Study Locations (1 sites)
Singapore National Eye Centre, Singapore, Singapore 168751 Singapore
Eligibility Criteria
Inclusion Criteria: We aim to recruit all eligible patients who attend Singapore General Hospital (SGH) Diabetes \& Metabolism Centre's (DMC) clinics and SingHealth Polyclinics (SHP)-Bukit Merah under the Singapore Integrated Diabetic Retinopathy Programme (SiDRP). Patients are eligible for the study if 1. Aged 21 years old and above, with diabetes, including type 1 and type 2, 2. Retinal photos of the patients can be taken with the fundus camera in the clinics, regardless of photos' quality, and 3. They are willing and capable of providing a written informed consent form. Exclusion Criteria: Patients meeting any of the exclusion criteria will be excluded from participation: 1. Patients who have difficulty in having retinal photos taken or have difficulties in completing the ocular examination protocols according to investigator's decision. 2. Any other contraindication(s) as indicated by the endocrinologists responsible for the patients. \-
Conditions Hormon Receptor Positive Breast Cancer, ...
Phase PHASE2
Enrollment 150
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This trial will study a type of breast cancer defined by the expression of hormone receptor in the cancer cells (HR+). Patients will be treated with ribociclib, a cyclin-dependent kinase inhibitor, and camizestrant, a selective estrogen receptor degrader (SERD) and complete ER antagonist. The main purpose of the Study is to analyze the efficacy (to find out how effective a treatment is) of ribociclib in combination with camizestrant in patients with advanced HR+ breast cancer who have received endocrine therapy (ET) in early breast cancer setting for at least 5 years, of which at least 2 years with aromatase inhibitor (AI). Ribociclib plus camizestrant efficacy will be determined by assessing the period from treatment initiation until disease progression, defined as progression free survival (PFS). The anticipated favorable clinical benefits of the combination of ribociclib and camizestrant therapy are projected to outweigh the risks of this treatment. This Study will be performed in full compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and all applicable local Good Clinical Practice (GCP) and regulations.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Camizestrant — Next-generation oral SERD molecule that is intended for the treatment of women and men with ER+ breast cancer. In addition to degradation of ERα, camizestrant also acts as a pure ER antagonist
  • Drug: Ribociclib — Selective inhibitor of CDK 4 and 6, with 50% inhibition (IC50) values of 0.01 μM (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated by binding to D-cyclins and are crucial to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates the cell cycle by phosphorylating the retinoblastoma protein (pRb).

Primary Outcomes

  • Progression Free Survival (PFS) (Up to 28 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-24
Completion: 2028-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: MedSIR
Contact Information
Study Contact:
MEDSIR
+ 34 932 214 135
contact.trials@medsir.org
Interventions
  • Drug: Camizestrant — Next-generation oral SERD molecule that is intended for the treatment of women and men with ER+ breast cancer. In addition to degradation of ERα, camizestrant also acts as a pure ER antagonist
  • Drug: Ribociclib — Selective inhibitor of CDK 4 and 6, with 50% inhibition (IC50) values of 0.01 μM (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated by binding to D-cyclins and are crucial to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates the cell cycle by phosphorylating the retinoblastoma protein (pRb).
Study Locations (16 sites)
Städtisches Klinikum Dessau, Dessau, Germany
Hospital General Universitario Dr. Balmis, Alicante, Spain
Hospital Clínic Barcelona, Barcelona, Spain
Hospital Dexeus, Barcelona, Spain
Institut Català d'Oncologia Girona - ICO Girona, Girona, Spain
HU Virgen de las Nieves, Granada, Spain
Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, Spain
Hospital Universitario de León, León, Spain
Beata Maria Ana, Madrid, Spain
Hospital Ramón y Cajal, Madrid, Spain
Eligibility Criteria
Inclusion Criteria: 1. Patient must be capable of understanding the purpose of the Study and have signed the written informed consent form (ICF) prior to beginning specific protocol procedures. 2. Female or male patients ≥ 18 years of age at the time of signing ICF. 3. Pre- or peri-menopausal women or men. are eligible if treated with a Luteinizing hormone-releasing hormone (LHRH) analogue. Treatment with a LHRH is recommended for at least 28 days prior to study treatment; if shorter, post-menopausal levels of serum estradiol/follicle-stimulating hormone \[FSH\] must be confirmed analytically prior to Study enrollment. 4. Post-menopausal women, defined by any of the following criteria: * Cessation of menses for at least 12 consecutive months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. * Documented bilateral surgical oophorectomy. 5. Documented histologically confirmed HR+ and human epidermal growth factor receptor 2 (HER2)-negative breast cancer according to the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines as per local assessment on the most recent analyzed biopsy. Therefore, tumors must be: o HR+ defined as ≥ 10% of tumor cells stain positive for estrogen receptor (ER) on immunohistochemistry (IHC), and HER2- defined as 0 or 1+ intensity on IHC, or 2+ intensity on IHC and no evidence of amplification on in situ hybridization (ISH). 6. Unresectable locally recurrent or metastatic disease confirmed by computerized tomography (CT) scan or magnetic resonance imaging (MRI) that is not amenable to resection with curative intent. 7. Patients must have received at least five years of adjuvant endocrine therapy, including at least two years of an AI (capped to 30% patients with treatment-free interval \[TFI\] ≥ 12 months. 8. Patients must have: * Radiological evidence of progression while on, or within 12 months of the end of (neo)adjuvant endocrine therapy (secondary endocrine resistance criteria), or * Radiological evidence of progression more than 12 months of the end of (neo)adjuvant endocrine therapy (endocrine sensitive criteria). 9. Patients receiving a CDK4/6 inhibitor-based therapy in the (neo)adjuvant setting are eligible if disease progression is confirmed more than 12 months following CDK4/6 inhibitor treatment completion in this scenario. 10. Evidence of measurable disease as per RECIST v.1.1, or non-measurable, but evaluable, disease, including bone-only disease with at least one lytic or mixed lytic-blastic bone lesion. 11. For patients receiving tamoxifen or toremifene, a washout period of 35 days (5 half-lives) prior to randomization is required 12. Patients must agree to provide and have available a FFPE tissue biopsy sample taken at the time of presentation with recurrent or metastatic disease. If this is not available, archived primary breast cancer specimen may be submitted 13. Adequate bone marrow and organ function: * Hematological (without platelet, red blood cell transfusion, and/or granulocyte colony-stimulating factor support within seven days before treatment initiation): White blood cell (WBC) count \> 3.0 x 109/L; absolute neutrophil count (ANC) ≥ 1.5 x 109/L; platelet count ≥ 100.0 x109/L; and hemoglobin ≥ 9.0 g/dL. * Hepatic: Serum albumin ≥ 2.5 g/dL; total serum bilirubin \< 1.5 x upper limit of normal (ULN) except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN; alkaline phosphatase (ALP) ≤ 2.5 x ULN (≤ 3 x ULN in patients with liver and/or bone metastases); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 1.5 x ULN (≤ 3 x ULN in patients with liver metastases); international normalized ratio (INR) \< 1.5. Prothrombin time (PT) or Prothrombin time-international normalized ratio (PT-INR) and activated partial thromboplastin time (aPTT)/partial thromboplastin time (PTT) ≤ 1.5 × ULN, except for subjects receiving coumarin-derivative anticoagulants, factor Xa inhibitors, or other similar anticoagulant therapy, who must have PT-INR within therapeutic range as deemed appropriate by the Investigator from product safety requirements (PSR). * Renal: Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50 mL/min as calculated by Cockcroft- Gault equation. 14. Patient must be available and willing to participate in the treatment and follow-up assessments as required. 15. Women of childbearing potential who are sexually active with a non-sterilized male partner must have a negative serum pregnancy test within 14 days before Study treatment initiation. In addition, they must agree to use one highly effective method of birth control from the time of screening until 4 weeks after the last dose of Study treatments. Female patients must refrain from egg cell donation and breastfeeding during this same period. Non-sterilized male partners of heterosexually active females of childbearing potential participants must use a male condom from the time of enrollment of their female partner, throughout their participation in the Study, and until 4 weeks after their female partner's last dose of Study intervention. 16. Male participants who are sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable highly effective method of contraception from the time of screening until 21 days after the last administration of the Study drug. Male participants must not donate or bank sperm during this same period. Female partners of childbearing potential of male participants must agree to use one highly effective method of contraception from the time of screening until 4 weeks after the last dose of Study treatments. 17. ECOG performance status of 0-1. 18. Minimum life expectancy of ≥ 6 months. Exclusion Criteria: 1. Formal contraindication to endocrine therapy defined as visceral crisis and/or rapidly or symptomatic progressive visceral disease. 2. Current participation in another therapeutic clinical trial. 3. Has previously been treated with any SERD, including camizestrant, experimental ETs or fulvestrant. 4. Prior systemic therapy for advanced disease. 5. Known active uncontrolled or symptomatic central nervous system (CNS) metastases and/or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases are eligible if they have been previously treated with local therapy, are clinically stable, and off anticonvulsants and steroids for at least 14 days before the first dose of Study treatment. 6. History of another primary malignancy except for the following: 1. Malignancy treated with curative intent with no known active disease ≥ 3 years before the first dose of Study treatment, and of very low potential risk for recurrence. 2. Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease. 3. Other exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin. Note: For other cancers considered to have a low risk of recurrence, discussion with the Medical Monitor is required. 7. Known allergy or hypersensitivity reaction to any investigational medicinal products (IMPs) or their incorporated substances. Note: Ribociclib is contraindicated for patients with hypersensitivity/allergy to peanut or soya. 8. History of malabsorption syndrome or other condition that would interfere with enteral absorption (ongoing gastrointestinal obstruction/motility disorder, malabsorption syndrome, or prior gastric bypass) or results in the inability or unwillingness to swallow pills. 9.
Conditions Depression, Cancer, Anxiety
Phase Not Applicable
Enrollment 540
Locations 18 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To examine the trajectories of anxiety and depression symptoms over the course of oncological disease, and to assess potential predictors-sociodemographic (age, sex, marital status, employment status), clinical (tumor location, stage, treatment type, general health), psychological (coping strategies, quality of life, cognitive difficulties, fear of recurrence), and physical activity-and their association with support needs and utilization of psychosocial services.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Psychosocial and clinical assessment — Participants complete standardized self-report questionnaires and undergo medical record review at three time points (baseline, 3 months, and 6 months) to assess psychological symptoms (anxiety, depression, somatization), coping strategies, quality of life, cognitive difficulties, physical activity, nutrition, supportive care needs, and informed decision-making in the context of cancer treatment. No experimental treatment or therapy is administered.

Primary Outcomes

  • Anxiety and depression symptoms (At the time of diagnosis or treatment initiation. Follow-up at 3 months: To assess the early evolution of symptoms. Follow-up at 6 months: To analyze the medium-term evolution.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-09-12
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 540 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundación Sociedad Española de Oncologia Médica
Principal Investigators:
  • Paula Dra. Jiménez Fonseca, MD-PhD (PRINCIPAL_INVESTIGATOR) - Sociedad Española de Oncología Médica (SEOM)
Contact Information
Study Contact:
Paula Dra. Jiménez Fonseca, MD-PhD
985106121
palucaji@hotmail.com
Dra. Paula Jiménez Fonseca, MD-PhD
985106121
palucaji@hotmail.com
Hospital Universitario Marqués de Valdecilla
Dra. Paula Jiménez Fonseca, MD-PhD
985106121
palucaji@hotmail.com
Hospital General Universitario de Ciudad Real
Interventions
  • Other: Psychosocial and clinical assessment — Participants complete standardized self-report questionnaires and undergo medical record review at three time points (baseline, 3 months, and 6 months) to assess psychological symptoms (anxiety, depression, somatization), coping strategies, quality of life, cognitive difficulties, physical activity, nutrition, supportive care needs, and informed decision-making in the context of cancer treatment. No experimental treatment or therapy is administered.
Study Locations (18 sites)
Hospital Universitario Marqués de Valdecilla, Santander, Cantabria 39008 Spain
Hospital General Universitario de Ciudad Real, Ciudad Real, Ciudad Real 13005 Spain
Hospital Universitario Virgen de la Luz, Cuenca, Cuenca 16002 Spain
Hospital General Universitario de Elche, Alicante, Elche 03203 Spain
Hospital Universitario del Sureste, Arganda, Madrid 28500 Spain
Hospital Universitario La Paz, Fuencarral-El Pardo, Madrid 28046 Spain
Hospital Universitario Fuenlabrada, Fuenlabrada, Madrid 28942 Spain
Hospital Universitario de La Princesa, Salamanca, Madrid 28006 Spain
Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid 28702 Spain
Hospital Universitario Infanta Leonor, Vallecas, Madrid 28031 Spain
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed diagnosis of solid cancer (non-hematologic) at any stage. * Adult age (\>18 years). * Candidate for perioperative systemic antineoplastic treatment or for advanced disease. * Willingness to participate in the study and sign the informed consent form, as appropriate, before initiating any study-specific procedures, in accordance with good clinical practice requirements and local regulations. Exclusion Criteria: * Presence of a pre-existing psychiatric or neurodegenerative disorder that impairs the patient's ability to participate in the study. * Presence of reading and writing difficulties that prevent the patient from completing the assessments. * Receipt of oncological treatment in the past 2 years for another cancer.
Conditions Atrial Fibrillation (AF), Hypertension, ...
Phase Not Applicable
Enrollment 30000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective observational cohort study conducted in Qujiang District, Zhejiang Province, China, aiming to evaluate the effectiveness of a comprehensive management program for elderly patients with chronic cardiovascular diseases (CVDs). The program integrates pharmacological treatment, lifestyle modification, health education, and long-term follow-up, with enhanced monitoring using 7-day ECG recording. The study focuses on major chronic CVDs including hypertension, coronary artery disease, atrial fibrillation, and heart failure. Approximately 30,000 participants aged ≥60 years will be enrolled and followed for up to 10 years.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up) — Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up) Enhanced monitoring with 7-day ECG

Primary Outcomes

  • Incidence of cardiovascular events (10 years)
  • All-cause and cardiovascular mortality (10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-03-01
Completion: 2035-03-01
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: true
Enrollment: 30000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Anzhen Hospital
Contact Information
Study Contact:
Le Zhou, MD
+8613840293506
13840293506@163.com
Le Zhou
+8613840293506
13840293506@163.com
Le Zhou, MD
010-13840293506
13840293506@163.com
Beijing Anzhen Hospital
Interventions
  • Device: Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up) — Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up) Enhanced monitoring with 7-day ECG
Study Locations (1 sites)
Beijing Anzhen Hospital, Beijing, Beijing Municipality 100029 China
Eligibility Criteria
Inclusion Criteria Age ≥60 years Resident of Qujiang District Diagnosed with chronic CVD (hypertension, coronary artery disease, heart failure, atrial fibrillation, or others) Able and willing to provide informed consent Exclusion Criteria Severe cognitive impairment or inability to provide consent Life expectancy \<1 year due to non-cardiovascular disease Participation refusal
Conditions Diabetes (Insulin-requiring, Type 1 or T...
Phase NA
Enrollment 116
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will demonstrate the safety and performance of the Novel Medtronic Experimental Automated Insulin Delivery system named MiniMed™ NMX8 system in people living with insulin-requiring diabetes in comparison with the MiniMed™ 780G system.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: NMX8 — Subjects will start using the MiniMed™ NMX8 system for 12 weeks
  • Device: 780G — Subjects will continue to use the MiniMed™ 780G for 12 weeks

Primary Outcomes

  • Primary Endpoint (During the 12-week study phase)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-19
Completion: 2027-03-17
Eligibility
Age: 2 Years and older
Sex: ALL
Volunteers: false
Enrollment: 116 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medtronic MiniMed, Inc.
Principal Investigators:
  • Pr. Ohad Cohen, MD (STUDY_CHAIR) - Medtronic MiniMed, Inc.
Contact Information
Study Contact:
Renée Tillie, PhD
+31627363854
renee.tillie@medtronic.com
Bérangère Lacroix
+41797187595
berangere.lacroix@medtronic.com
Christophe De Block
Universitair Ziekenhuis Antwerpen
Interventions
  • Device: NMX8 — Subjects will start using the MiniMed™ NMX8 system for 12 weeks
  • Device: 780G — Subjects will continue to use the MiniMed™ 780G for 12 weeks
Study Locations (9 sites)
Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
Cliniques Universitaires de Bruxelles - Hôpital Erasme, Brussels, Belgium
UZ Leuven, Leuven, Belgium
UZ Leuven, Leuven, Belgium
Steno Diabetes Center Aarhus, Aarhus, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark
Sheba Medical Center, Edmond and Lily Safra Children's Hospital, Ramat Gan, Israel
Sheba Medical Center, Ramat Gan, Israel
University Medical Centre Ljubljana, Ljubljana, Slovenia
Eligibility Criteria
Inclusion Criteria: 1. Is aged ≥2 years old at time of screening. 2. Has a clinical diagnosis of Type 1 or Type 2 diabetes for ≥ 6 months prior to screening as determined via medical record by an individual qualified to make a medical diagnosis. 3. Is on MiniMed™ 780G with Simplera Sync sensor for at least 3 months before screening. 4. Has a glycosylated hemoglobin (HbA1c) \<11% (97 mmol/mol) at time of screening visit as processed at Point of Care (PoC) or local lab. 5. Must have a minimum daily insulin requirement (Total Daily Dose) of ≥ 6 units and a maximum of 250 units 6. Willing to switch to approved insulin per insulin pump labeling. 7. Investigator has confidence that the subject, parent(s)/legal guardian(s) can successfully operate all study devices and is capable of adhering to study visit schedule per protocol. 8. Subject, Parent(s)/legal guardian(s) is willing to participate in all training sessions as directed by study staff. 9. Subject, Parent(s)/legal guardian(s) is willing and able to provide written informed consent. 10. For subject with Type 2 Diabetes only: Is on stable dose of anti-diabetic medication (other than insulin) (e.g., pramlintide, DPP-4 inhibitor, GLP-1 and GIP agonists/mimetics, metformin, SGLT2 inhibitors) for the last 3 months prior to screening. NB: Subject should not change type or dose of medication during the course of the study. 11. For Israel only: Subject, Parents(s)/legal guardian(s) is fluent in English. Exclusion Criteria: 1. Has Addison's disease, growth hormone deficiency, hypopituitarism or definite gastroparesis, uncontrolled coeliac disease, uncontrolled thyroid disorder, or poorly controlled asthma, per investigator judgment. 2. For subjects with Type 1 Diabetes only: Is using any anti-diabetic medication other than insulin 6 months before screening or plan on using during the study (e.g., pramlintide, DPP-4 inhibitor, GLP-1 and GIP agonists/mimetics, metformin, SGLT2 inhibitors). 3. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit, or plans to take any chronically oral, injectable, or IV glucocorticoids during the course of the study, per investigator judgement 4. Has had renal failure defined by creatinine clearance \<30 ml/min, as assessed by local lab test ≤ 6 months before screening or performed at screening at local lab, as defined by the creatinine-based Cockcroft, CKD-EPI or MDRD equations. 5. Has active or severe retinopathy in the last 6 months before screening 6. Has any unresolved adverse skin conditions in the area of sensor placement (e.g. psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection). 7. Has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment. 8. History of 2 or more DKA events in the last 3 months before screening. 9. Has had Hyperosmolar Hyperglycemic State (HHS) in the last 6 months before screening. 10. Is using hydroxyurea at time of screening or plans to use it during the study 11. Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study. 12. Women who are breastfeeding. 13. Is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or device in the last 2 weeks before screening, as per investigator judgment. 14. Subject is currently abusing illicit drugs, marijuana, alcohol or prescription drugs (other than nicotine), per investigator judgment. 15. Subject, Parent(s)/legal guardian(s) are part of research staff involved with the study. 16. Subject, Parent(s)/legal guardian (s) are legally incompetent, illiterate, or vulnerable.
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase PHASE2
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial studies how well imlunestrant and abemaciclib work in treating patients with estrogen receptor positive (ER+) breast cancer who have tumor remaining in the blood following treatment (minimal residual disease). Estrogen can cause the growth of breast cancer cells. Imlunestrant lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Imlunestrant and abemaciclib may be effective in treating patients with ER+ breast cancer who have minimal residual disease.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Abemaciclib — Given PO
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Drug: Imlunestrant — Given PO
  • Other: Questionnaire Administration — Ancillary studies
  • Procedure: Radiologic Imaging Procedure — Undergo radiologic scans

Primary Outcomes

  • Rate of circulating tumor deoxyribonucleic acid (ctDNA) clearance (After 12 cycles (Cycle length = 28 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-18
Completion: 2031-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jonsson Comprehensive Cancer Center
Principal Investigators:
  • Marla Lipsyc-Sharf (PRINCIPAL_INVESTIGATOR) - UCLA / Jonsson Comprehensive Cancer Center
Contact Information
Study Contact:
Ruth Gonzalez
3107944376
rngonzalez@mednet.ucla.edu
Ruth Gonzalez
310-794-4376
rngonzalez@mednet.ucla.edu
UCLA / Jonsson Comprehensive Cancer Center
Marla Lipsyc-Sharf, MD
UCLA / Jonsson Comprehensive Cancer Center
Interventions
  • Drug: Abemaciclib — Given PO
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Drug: Imlunestrant — Given PO
  • Other: Questionnaire Administration — Ancillary studies
  • Procedure: Radiologic Imaging Procedure — Undergo radiologic scans
Study Locations (1 sites)
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California 90095 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have localized ER+ (≥ 10% on surgical pathology), HER2 negative, any grade, invasive breast cancer. Pathological stage (from time of surgery, including patients who received neoadjuvant therapy) I - III by American Joint Committee on Cancer (AJCC) 8th edition staging * Note: Invasive breast cancer must be ER+ in ≥ 10% of the cells and HER2 negative (immunohistochemistry \[IHC\] 0 or 1+ and/or fluorescence in situ hybridization \[FISH\] negative with a ratio \< 2) by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. For Immunohistochemistry (IHC) 2+, the tumor must be FISH negative with a ratio \< 2. ER, progesterone receptor (PR) and HER2 measurements should be performed according to institutional (local) guidelines, in a Clinical Laboratory Improvement Act (CLIA)-approved setting * Detectable ctDNA in a CLIA-certified lab (separate pre-screening consent available) within the past six months. Participants must have no clinical or radiographic evidence of recurrence as determined by the treating investigator * Confirmation of adequate archival tissue (either initial biopsy or surgical specimen) (15-20 unstained slides cut at 5 µm or 1 block) required before study entry. If adequate surgical tissue is available, this is preferred. Otherwise tissue from diagnostic biopsy is acceptable. If adequate tissue not available, principal investigator (PI) approval is required prior to study entry * No prior history of other malignancies within past 5 years (besides breast cancer as per inclusion #1). Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: ductal carcinoma in situ of the breast, cervical cancer in situ, melanoma in situ, and basal cell or squamous cell carcinoma of the skin. No concurrent malignancy or other serious medical condition as deemed by the investigator * Participants may or may not have received (neo)adjuvant chemotherapy and/or biological therapy at the time of screening, with no more than grade 1 residual toxicity (except ≤ grade 2 neuropathy or ≤ grade 2 alopecia) * Participants may or may not have received adjuvant radiotherapy, with no more than grade 1 residual toxicity * Pre- and postmenopausal women and men are eligible. Premenopausal women must have a negative serum pregnancy test at time of screening * Pregnancy testing does not need to be pursued in female patients who are: * Age ≥ 60 years; OR * Age \< 60 with intact uterus AND amenorrhea for 12 consecutive months or more AND estrogen (estradiol) levels within postmenopausal range * OR status-post bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation * Must be ≥ 18 years of age * History of CDK 4/6 inhibitor is permitted provided the last dose was more than 6 months ago (from consent date) * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnofsky ≥ 70%) * Patients must currently be on endocrine therapy in the adjuvant setting and must have received (neo) adjuvant endocrine therapy for at least 24 months (cumulative duration) * Ability to understand and the willingness to sign a written informed consent document. Patient must sign the informed consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements * Participants must currently be receiving adjuvant endocrine therapy and have been on adjuvant endocrine therapy for at least 2 years. Adjuvant endocrine therapy can be either tamoxifen or aromatase inhibitor (AI), i.e prior use of any AI, including letrozole, anastrozole or exemestane, or tamoxifen is allowed. Concurrent gonadotrophin releasing hormone (GNRH) agonist is required with AI in pre - and/or peri-menopausal patients and men * Absolute neutrophil count ≥ 1.5 × 10\^9/L * Platelets ≥ 100 × 10\^9/L * Hemoglobin ≥ 9.0 g/dL * Serum creatinine \< 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x institutional upper limit of normal (ULN) * Total bilirubin \< institutional 1.5 times ULN; or total bilirubin ≤ 3.0 x institutional ULN. Patients with Gilbert's Syndrome with a total bilirubin ≤ 2.0 times ULN and direct bilirubin within normal limits are permitted * The patient is able to swallow oral medications Exclusion Criteria: * Participants with metastatic disease (including contralateral axillary lymph nodes) or inflammatory breast cancer. Of note, if a patient had locally advanced breast cancer leading to inflammation, this would not exclude the patient on the grounds of inflammatory carcinoma * Participants who have had CDK 4/6 inhibitor therapy within the past 6 months. Use of prior CDK 4/6 inhibitor with last dose more than 6 months ago is permitted * Participants who are receiving any other anti-cancer investigational agents. Participation in other observational studies is permitted * History of other malignancies within past 5 years, except ductal carcinoma in situ of the breast, cervical cancer in situ, melanoma in situ, and basal cell or squamous cell carcinoma of the skin. No concurrent malignancy or other serious medical condition as deemed by the investigator * Herbal products and supplements will generally not be allowed, but specific supplements (such as cannabidiol \[CBD\] oil) can be considered on a case-by-case basis by Overall PI * Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment (e.g. estimated creatinine clearance \< 30ml/min), unstable angina pectoris, cardiac arrhythmia, a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements. Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, stomach resection, or small bowel resection) are ineligible. Patient with active systemic bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\]). Screening for HIV and hepatitis is not required for enrollment * The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest * A history of venous thromboembolism (VTE): deep vein thrombus or pulmonary embolism. An exception can be made for patients with a history of an uncomplicated venous catheter-related occlusion. The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest * History of hypersensitivity to imlunestrant, abemaciclib or any of the components in either medication * HIV-positive participants not on antiretroviral therapy are at increased risk of lethal infections when treated with marrow-suppressive therapy and should not be enrolled until their HIV is managed. If the HIV is well controlled, participants may participate in this study * Pregnant women are excluded from this study because embryo-fetal toxicity is a potential side effect of abemaciclib and imlunestrant. For this reason, women of child-bearing potential (WOCBP) and men must agree to use highly effective contraception prior to
Conditions Unipolar Depression, Bipolar Depression
Phase PHASE4
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Vortioxetine — Vortioxetine, once daily, for 8 weeks
  • Drug: Cariprazine (Augmentation Phase) — Participants who do not meet remission criteria will enter a second 8-week augmentation phase (Weeks 9-16). During this phase, cariprazine will be added to the existing regimen, administered orally once daily in the morning, starting at 1.5 mg/day and titrated up to 3.0 mg/day in one week.

Primary Outcomes

  • Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score (Baseline, Week 2, Week 8, Week 10, Week 16)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-02-17
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Aysegul Ozerdem, MD, PhD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
  • Deniz Ceylan, MD, PhD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Scott E. Feeder
507-255-1975
feeder.scott@mayo.edu
Scott E. Feeder
507-255-1975
Mayo Clinic in Rochester
Aysegul Ozerdem, MD, PhD
Mayo Clinic in Rochester
Interventions
  • Drug: Vortioxetine — Vortioxetine, once daily, for 8 weeks
  • Drug: Cariprazine (Augmentation Phase) — Participants who do not meet remission criteria will enter a second 8-week augmentation phase (Weeks 9-16). During this phase, cariprazine will be added to the existing regimen, administered orally once daily in the morning, starting at 1.5 mg/day and titrated up to 3.0 mg/day in one week.
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria Participants must meet all the following criteria to be eligible for the study: 1. Adult females and males, aged 18-65 years 2. Must have the capacity to understand study procedures, to comply with them for the entire length of the study, and to provide informed consent. 3. Current major depressive episodes associated with MDD, BD-I, or BD-II, confirmed using the SCID-IV-CV. If a participant has already completed a structured diagnostic interview within the last 2 years or participated in any of the following studies and provided consent to use their information in future studies: (IRB 19-001722, IRB: 23-004500, IRB: 24-013228, IRB: 25-005856, IRB: 25-007244), those SCID results can be used for the EDIT-ANDRE study. 4. Symptom severity score on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) \> 10. 5. Ability to travel for assessment visits. 6. Negative urine pregnancy test for people of childbearing potential 7. People of childbearing potential must be using an acceptable method of birth control during the study, such as hormonal contraception, intrauterine device, bilateral tubal ligation, partner's documented vasectomy, or complete abstinence from intercourse with childbearing potential, with barrier methods permitted only when used in combination with one of these primary methods. 8. BD-I patients must be on stable dose of at least one mood stabilizer (i.e., lithium, valproate, or a mood-stabilizing atypical antipsychotic at least for one month) at the time of enrollment. Patients with BD-II who enroll in the study while currently taking a mood stabilizer (including lithium, valproate, or lamotrigine) must have been on a stable dose of that medication for a minimum of one month before enrollment. Exclusion Criteria All candidates meeting any of the following criteria at baseline will be excluded from study participation: 1. Individuals who cannot understand English will not be enrolled because informed consent, study procedures, and interviews require comprehension of English. 2. Inability to provide written, voluntary informed consent due to but not limited to being under conservatorship, guardianship, commitment, or currently undergoing involuntary psychiatric hospitalization. 3. Failure to score at least 75% on a 4-item comprehension assessment related to study goals, risks, and benefits 4. For BD-I: not having used at least one mood stabilizer (e.g., lithium, valproate, or mood-stabilizing antipsychotics) at a stable dose and within a therapeutically effective antimanic range for a minimum of one month. 5. History of treatment-refractory depression, defined as non-response to two or more antidepressant or mood-stabilizing regimens despite adequate dose, duration, and adherence during the current episode. 6. Participants with active suicidal ideation, defined as a MADRS item #10 score greater than 4 or a "yes" response to item #4 (ideation with intent) or item #5 (ideation with plan) on the C-SSRS, will be excluded 7. A medically serious suicide attempt within the past 6 months, defined as requiring emergency department evaluation, a medical procedure, or admission to a hospital (e.g., internal medicine, cardiology, or ICU) 8. Current use of monoamine oxidase inhibitors or use within 14 days following discontinuation of a monoamine oxidase inhibitor 9. Presence of mixed symptoms of depression, defined as a YMRS score ≥12 10. Current use of any of the study medications (e.g., vortioxetine, or cariprazine) at the time of enrollment (previous use of these medications is acceptable) 11. Prior hypersensitivity reaction to any of the study medications or documented non-response to any of the study medications at the maximum therapeutic dose 12. A history of seizure disorder 13. Recent use of long half-life psychotropic medications, including fluoxetine (in patients with BD and MDD) and long acting injectable forms of antipsychotics (mainly in BD II and MDD) within the past 4 weeks. 14. Active psychosis, defined as a YMRS item #8 score \>4 or diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or schizophreniform disorder as determined by structured clinical interview 15. Current drug or alcohol use disorder (excluding nicotine); full remission for at least 3 months is required for eligibility 16. Positive toxicology screen for illicit substances (e.g., cocaine, methamphetamine, illegal opiates). Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less. 17. Individuals who are pregnant, lactating, trying to conceive, or not using adequate contraception (e.g., hormonal contraception, intrauterine device, tubal ligation, or condoms) 18. Any active or unstable medical condition judged by the principal investigator to confer excessive risk 19. Clinically significant laboratory abnormality, uncontrolled hypertension (blood pressure \>160/100 mmHg), or tachycardia (heart rate \>110 bpm) 20. Significant renal, hepatic, or cardiac disease; malignancy; autoimmune disease; or chronic kidney disease \> stage IIIa (estimated GFR \< 60 mL/min/1.73 m²) 21. History of traumatic brain injury defined as loss of consciousness for 5 minutes and related to a trauma event 22. Gastric bypass, specifically Roux-en-Y 23. Clinical current diagnosis of delirium, encephalopathy, intellectual disability or cognitive disorder (mild or major neurocognitive disorder) 24. Currently receiving electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), or deep brain stimulation (DBS) as acute or maintenance treatment 25. Current use of systemic steroids, chemotherapy, and radiotherapy 26. Daily use of lorazepam (Ativan) \>4 mg/day, or equivalent doses of other benzodiazepines (e.g., clonazepam \>1 mg, alprazolam \>2 mg, diazepam \>20 mg) 27. No access to smartphones, internet 28. Other Axis I or II diagnoses, by clinical judgments that are the current reason for treatment evaluation or play a large part of the current symptom presentation 29. Ongoing treatment with opioid agonists will constitute an exclusion criterion. In contrast, other ongoing treatments, such as alcohol relapse prevention agents or ADHD pharmacotherapy, will not be considered exclusion criteria, provided that no treatment initiation or significant dose adjustment has occurred within the past 4 weeks. All candidates meeting any of the following criteria at baseline will be excluded from the Phase 2 (cariprazine add-on) of the study: 1. Meeting symptomatic remission criteria based on MADRS (≤ 10). 2. Current use of a strong or moderate CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, fluconazole, or verapamil) strong or moderate CYP3A4 inducer (e.g., carbamazepine, rifampin, phenytoin, or St. John's Wort), due to potential pharmacokinetic interactions with cariprazine. 3. Diagnosis of BD-I with concurrent use of an antipsychotic agent as a mood stabilizer.